Clinical progress note: Hepatitis A virus

Despite a decline in hepatitis A virus (HAV) incidence following vaccine introduction, HAV remains a public health concern in the United States. Recent multi‐state outbreaks have demonstrated that HAV can re‐emerge and highlight inequities in vaccine coverage or access, outbreak response, and in those with social or health risk factors. Continued investment in prevention, particularly vaccination and surveillance, is essential to prevent resurgence. Hospitalization offers a critical opportunity to address these gaps and provide equitable protection for at‐risk populations.